Bausch + Lomb (NYSE:BLCO) is back in focus after CEO Brent Saunders exited on October 12 and board chairman Thomas J. Appio stepped in as interim chief executive.
The leadership handover comes as the eye care group signals plans to lift its full-year 2026 adjusted EBITDA outlook following what it describes as strong third-quarter performance and ongoing improvements.
Bausch + Lomb shares have been edging higher, with a 7.79% 90 day share price return and a 5.13% year to date share price gain. The 1 year total shareholder return of 10.46% points to gradually building momentum around the business as leadership and guidance reset.
Spot fresh leadership stories like Bausch + Lomb's, alongside other potential momentum resets, with our hand-picked 20 high quality undiscovered gems.Bulls point to rising EBITDA guidance and fresh leadership focus at Bausch + Lomb, while bears highlight the current loss and parent company overlap. Which story does the valuation math lean toward next?
Most Popular Narrative: 10% Undervalued
At a last close of $17.43 against a narrative fair value of $19.39, Bausch + Lomb is framed as modestly mispriced, with that gap hinging on how quickly earnings catch up to its eye care pipeline.
Disciplined execution under the Vision 27 financial excellence program, including SG&A mix optimization, manufacturing efficiencies and focused R&D spend on near to mid term launch assets, is expected to support adjusted EBITDA growth above sales growth and drive expanding net margins and earnings power.
See why 3 investors see Bausch + Lomb as 10% undervalued.
Result: Fair Value of $19.39 (UNDERVALUED)
Still, the Bausch + Lomb story can be knocked off course if its loss of $171 million persists longer than analysts model or if refractive procedure softness drags on surgical demand.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
Mixed mood around Bausch + Lomb is clear, with solid optimism on future potential set against live concerns on profitability and execution risk. If you want to move fast and ground your own view in the numbers and context that matter most to you, start by weighing the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Bausch + Lomb?
Do not stop at Bausch + Lomb. Broaden your watchlist with ideas filtered by quality, resilience and income so your next move is deliberate, not accidental.
- Target resilient compounders by scanning a universe of stocks with strong balance sheets and fundamentals through the list of solid balance sheet and fundamentals (26 results).
- Hunt for mispriced opportunities by focusing on businesses that combine quality with attractive valuations using the 29 high quality undervalued stocks.
- Build a steadier income stream by reviewing companies that offer robust payout profiles through the 6 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com